PMV Pharmaceuticals, Inc.
NASDAQ: PMVP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David H. Mack
- Employees
- 47
- Headquarters
- Princeton, United States
- IPO year
- 2020
- Market cap
- $62.9M
- Website
- https://www.pmvpharma.com
Loading PMVP…
Loading profile data…Frequently asked questions about PMVP
What does PMV Pharmaceuticals, Inc. (PMVP) do?
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation,...
Where does PMVP trade?
PMV Pharmaceuticals, Inc. (PMVP) trades on the NASDAQ Global Select.
What sector is PMVP in?
PMV Pharmaceuticals, Inc. (PMVP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of PMV Pharmaceuticals, Inc.?
David H. Mack is the chief executive officer of PMV Pharmaceuticals, Inc. (PMVP).
Where is PMV Pharmaceuticals, Inc. headquartered?
PMV Pharmaceuticals, Inc. is headquartered in United States.
Does PMVP pay a dividend?
PMV Pharmaceuticals, Inc. (PMVP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PMVP go public?
PMV Pharmaceuticals, Inc. (PMVP) completed its initial public offering in 2020.